2026-04-14T08:04:32Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1801022025-12-05T12:42:06Zcom_2072_1057col_2072_478916col_2072_478917

Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis Hanna, Catherine R. Robles Zurita, José A. Briggs, Andrew Harkin, Andrea Kelly, Caroline McQueen, John Allan, Karen Pearson, Sarah Hollander, Henrik Glimelius, Bengt Salazar Soler, Ramón Segelov, Eva Saunders, Mark Iveson, Tim Jones, Robert J. Boyd, Kathleen A. Càncer colorectal Economia de la salut Cancer chemotherapy Medical economics Background: The Short Course Oncology Treatment (SCOT) trial demonstrated non-inferiority, less toxicity, and cost-effectiveness from a UK perspective of 3 versus 6 months of oxaliplatin-based chemotherapy for patients with colorectal cancer. This study assessed the cost-effectiveness of shorter treatment and the budget impact of implementing trial findings from the perspectives of all countries recruited to SCOT: Australia, Denmark, New Zealand, Spain, Sweden, and the United Kingdom. Patients and methods: Individual cost-utility analyses were performed from the perspective of each country. Resource, quality of life, and survival estimates from the SCOT trial (N = 6065) were used. Probabilistic sensitivity analysis and subgroup analyses were undertaken. Using undiscounted costs from these cost-utility analyses, the impact on country-specific healthcare budgets of implementing the SCOT trial findings was calculated over a 5-year period. The currency used was US dollars (US$), and 2019 was the base year. One-way and scenario sensitivity analysis addressed uncertainty within the budget impact analysis. Results: Three months of treatment were cost saving and cost-effective compared to 6 months from the perspective of all countries. The incremental net monetary benefit per patient ranged from US$8972 (Spain) to US$13,884 (Denmark). The healthcare budget impact over 5 years for the base-case scenario ranged from US$3.6 million (New Zealand) to US$61.4 million (UK) and totaled over US$150 million across all countries. Conclusion: This study has widened the transferability of results from the SCOT trial, showing that shorter treatment is cost-effective from a multi-country perspective. The vast savings from implementation could fully justify the investment in conducting the SCOT trial. 2021-09-17T11:54:47Z 2021-09-17T11:54:47Z 2021-09-01 2021-09-16T08:56:52Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1533-0028 https://hdl.handle.net/2445/180102 33992542 eng Reproducció del document publicat a: https://doi.org/10.1016/j.clcc.2021.04.001 Clinical Colorectal Cancer, 2021, vol. 20,num. 3, p. 236-244 https://doi.org/10.1016/j.clcc.2021.04.001 cc by (c) Hanna, Catherine R. et al, 2021 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess 9 p. application/pdf Elsevier Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))